Menu Search
Equities

Abeona Therapeutics Inc

PCJ:FRA

Abeona Therapeutics Inc

Actions
  • Price (EUR)3.80
  • Today's Change-0.10 / -2.56%
  • Shares traded130.00
  • 1 Year change+42.43%
  • Beta--
Data delayed at least 15 minutes, as of May 15 2024 07:02 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Abeona Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing cell and gene therapies for life-threatening diseases. The Company’s lead clinical program is for prademagene zamikeracel (pz-cel), its investigational autologous, COL7A1 gene-corrected epidermal sheets currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The Company’s fully integrated cell and gene therapy Good Manufacturing Practice (cGMP) manufacturing facility served as the manufacturing site for pz-cel used in its Phase III VIITAL trial and is capable of supporting commercial production of pz-cel upon FDA approval. The Company’s development portfolio also features adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with high unmet medical need. The Company’s novel, next-generation AAV capsids are being evaluated to improve tropism profiles for a variety of devastating diseases.

  • Revenue in USD (TTM)3.50m
  • Net income in USD-54.19m
  • Incorporated1989
  • Employees84.00
  • Location
    Abeona Therapeutics Inc6555 CARNEGIE AVE, 4TH FLOORCLEVELAND 44103United StatesUSA
  • Phone+1 (646) 813-4701
  • Fax+1 (302) 655-5049
  • Websitehttps://abeonatherapeutics.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.